BioTuesdays
Adamis Pharma

Adamis Pharma gets second CRL for ZIMHI

Adamis Pharmaceuticals (NASDAQ:ADMP) received a second complete response letter (CRL) from the FDA regarding its ZIMHI high dose naloxone injection product for the treatment of opioid overdose. The FDA issued its first...

Opthea-Logo

SVB Leerink starts Opthea at OP; PT $33

SVB Leerink launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $33 price target. The stock closed at $13.19 on Nov. 10. “The basis for our recommendation and valuation is our forecast for revenue...